期刊
CURRENT MEDICAL RESEARCH AND OPINION
卷 39, 期 1, 页码 123-129出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/03007995.2022.2148459
关键词
Analgesics; opioid; chronic pain; drug tapering; tapentadol
Tapentadol is an atypical opioid with improved gastrointestinal tolerability. This article provides an overview of opioid therapy in non-cancer pain, focusing on tapering of tapentadol in patients with chronic non-cancer pain. A flow chart is provided to guide clinicians in tapering tapentadol treatment based on individual patient characteristics and response to dosage reduction. Tapering strategies for tapentadol need further research.
ObjectiveDue to its opioid and non-opioid mechanism of action, tapentadol is considered an atypical opioid with improved gastrointestinal tolerability versus traditional opioids. As for all opioid analgesics it is important to understand how to discontinue a treatment when it is not needed anymore. The aim of this article was to provide an overview of opioid therapy in non-cancer pain, with a specific focus on tapering of tapentadol in patients with chronic non-cancer pain, and suggestions on how to achieve tapering.MethodsStudies for this narrative review were identified via PubMed using a structured search strategy, focusing on management of chronic non-cancer pain with opioids, and the efficacy, tolerability, and pharmacology of tapentadol prolonged release. Publications were limited to English-language articles published within the last similar to 10 years.ResultsThe review discusses the use and discontinuation of opioids in general, as well clinical data on discontinuation of tapentadol specifically. We provide a flow chart, which can be used by clinicians in the context of their own clinical experience to appropriately taper tapentadol in patients with chronic non-cancer pain. The flow chart can be easily tailored to individual patient characteristics, duration of tapentadol treatment, response to progressive dosage reduction, and likelihood of withdrawal symptom occurrence. ConclusionsWhile tapentadol is associated with a low frequency of opioid withdrawal symptoms after abrupt discontinuation, use of a tapering strategy is prudent. Tapering strategies developed for opioids in general can potentially be safely individualized in tapentadol-treated patients, although research on tapering strategies for tapentadol is required.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据